

Hossein Jadvar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6919662/publications.pdf>

Version: 2024-02-01

141
papers

5,154
citations

101384

36
h-index

95083

68
g-index

145
all docs

145
docs citations

145
times ranked

5881
citing authors

#	ARTICLE	IF	CITATIONS
1	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology</i> , The, 2019, 20, 1286-1294.	5.1	338
2	Prostate Cancer: PET with ¹⁸ F-FDG, ¹⁸ F- or ¹¹ C-Acetate, and ¹⁸ F- or ¹¹ C-Choline. <i>Journal of Nuclear Medicine</i> , 2011, 52, 81-89.	2.8	288
3	The SNMMI Practice Guideline for Therapy of Thyroid Disease with ¹³¹ I 3.0. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1633-1651.	2.8	229
4	¹⁸ F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1820-1827.	2.8	203
5	Incidental Colonic Fluorodeoxyglucose Uptake: Correlation with Colonoscopic and Histopathologic Findings. <i>Radiology</i> , 2002, 224, 783-787.	3.6	187
6	A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. <i>European Journal of Radiology</i> , 2008, 65, 449-461.	1.2	156
7	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	5.1	153
8	PSMA Theranostics: Current Status and Future Directions. <i>Molecular Imaging</i> , 2018, 17, 153601211877606.	0.7	150
9	Competitive advantage of PET/MRI. <i>European Journal of Radiology</i> , 2014, 83, 84-94.	1.2	149
10	Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 5-10.	3.3	137
11	Is There Use for FDG-PET in Prostate Cancer?. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 502-506.	2.5	128
12	Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 637-643.	0.7	125
13	PET and PET/CT in Pediatric Oncology. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 316-331.	2.5	115
14	Baseline ¹⁸ F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1195-1201.	2.8	110
15	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1963-1996.	0.8	107
16	Molecular Imaging of Prostate Cancer: PET Radiotracers. <i>American Journal of Roentgenology</i> , 2012, 199, 278-291.	1.0	95
17	Radiotheranostics in Cancer Diagnosis and Management. <i>Radiology</i> , 2018, 286, 388-400.	3.6	91
18	Diagnostic utility of FDG PET in multiple myeloma. <i>Skeletal Radiology</i> , 2002, 31, 690-694.	1.2	89

#	ARTICLE	IF	CITATIONS
19	Sodium 18F-Fluoride PET/CT of Bone, Joint, and Other Disorders. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 58-65.	2.5	87
20	Appropriate Use Criteria for ¹⁸ F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. <i>Journal of Nuclear Medicine</i> , 2017, 58, 2026-2037.	2.8	78
21	Molecular Imaging of Prostate Cancer with PET. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1685-1688.	2.8	74
22	Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. <i>Nature Reviews Urology</i> , 2009, 6, 317-323.	1.9	73
23	Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. <i>American Journal of Roentgenology</i> , 2017, 209, 277-288.	1.0	68
24	[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2008, 13, 42-47.	1.0	67
25	Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. <i>Molecular Imaging and Biology</i> , 2018, 20, 501-509.	1.3	67
26	[F-18]Fluorodeoxyglucose Positron Emission Tomography and Positron Emission Tomography. <i>Journal of Computer Assisted Tomography</i> , 2007, 31, 223-228.	0.5	66
27	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68.	2.8	61
28	Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 580-601.	1.0	55
29	Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography. <i>Molecular Imaging and Biology</i> , 1999, 2, 153-158.	0.3	53
30	Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies. <i>PET Clinics</i> , 2018, 13, 623-634.	1.5	47
31	FDG PET in Prostate Cancer. <i>PET Clinics</i> , 2009, 4, 155-161.	1.5	46
32	Targeted α -Particle Therapy of Bone Metastases in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 966-971.	0.7	46
33	PSMA PET in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1131-1132.	2.8	46
34	The Effect of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography on the Management of Cutaneous Malignant Melanoma. <i>Clinical Nuclear Medicine</i> , 2000, 25, 48.	0.7	43
35	FDG PET in suspected recurrent and metastatic prostate cancer. <i>Oncology Reports</i> , 2003, 10, 1485-8.	1.2	43
36	Targeted Radionuclide Therapy: Practical Applications and Future Prospects. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31804.	3.6	42

#	ARTICLE	IF	CITATIONS
37	PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 25S-29S.	2.8	38
38	Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging. <i>American Journal of Roentgenology</i> , 2018, 210, W245-W263.	1.0	37
39	¹⁸ F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA \geq 1 ng/mL After Definitive Primary Treatment. <i>Clinical Nuclear Medicine</i> , 2019, 44, e128-e132.	0.7	37
40	Musculoskeletal system. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 254-261.	2.5	36
41	One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 195-199.	0.7	34
42	Low-count whole-body PET with deep learning in a multicenter and externally validated study. <i>Npj Digital Medicine</i> , 2021, 4, 127.	5.7	34
43	[¹⁸ F]-fluorodeoxyglucose PET-CT of the normal prostate gland. <i>Annals of Nuclear Medicine</i> , 2008, 22, 787-793.	1.2	33
44	Pharmacologic Interventions in Nuclear Radiology: Indications, Imaging Protocols, and Clinical Results. <i>Radiographics</i> , 2002, 22, 477-490.	1.4	32
45	Update on advances in molecular PET in urological oncology. <i>Japanese Journal of Radiology</i> , 2016, 34, 470-485.	1.0	31
46	PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin. <i>PET Clinics</i> , 2018, 13, 609-621.	1.5	31
47	Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 19S-24S.	2.8	30
48	Preservation of retinotopic map in retinal degeneration. <i>Experimental Eye Research</i> , 2012, 98, 88-96.	1.2	29
49	PET in pediatric diseases. <i>Radiologic Clinics of North America</i> , 2005, 43, 135-152.	0.9	28
50	Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analyses. <i>Tomography</i> , 2015, 1, 18-22.	0.8	28
51	A reusable perfusion supporting tissue-mimicking material for ultrasound hyperthermia phantoms. <i>Medical Physics</i> , 1990, 17, 380-390.	1.6	26
52	Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1524-1530.	2.8	25
53	Glucose metabolism of human prostate cancer mouse xenografts. <i>Molecular Imaging</i> , 2005, 4, 91-7.	0.7	25
54	SPECT and PET in the Evaluation of Coronary Artery Disease. <i>Radiographics</i> , 1999, 19, 915-926.	1.4	24

#	ARTICLE	IF	CITATIONS
55	Evolving Cardiac Conduction Phenotypes in Developing Zebrafish Larvae: Implications to Drug Sensitivity. <i>Zebrafish</i> , 2010, 7, 325-331.	0.5	24
56	PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1803-1811.	1.2	24
57	Hepatocellular Carcinoma and Gastroenteropancreatic Neuroendocrine Tumors: Potential Role of Other Positron Emission Tomography Radiotracers. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 247-254.	2.5	23
58	Effect of Atropine and Sincalide on the Intestinal Uptake of F-18 Fluorodeoxyglucose. <i>Clinical Nuclear Medicine</i> , 1999, 24, 965.	0.7	23
59	2-Deoxy-2-[F-18]Fluoro-d-Glucoseâ€™Positron Emission Tomography/Computed Tomography Imaging Evaluation of Esophageal Cancer. <i>Molecular Imaging and Biology</i> , 2006, 8, 193-200.	1.3	22
60	Molecular Imaging of Prostate Cancer: A Concise Synopsis. <i>Molecular Imaging</i> , 2009, 8, 7290.2009.00010.	0.7	22
61	The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. <i>Prostate</i> , 2010, 70, 1359-1370.	1.2	21
62	Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. <i>Clinical Nuclear Medicine</i> , 2018, 43, e226-e231.	0.7	20
63	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2300-2309.	3.3	20
64	Actinomycosis Mimicking Anastomatic Recurrent Esophageal Cancer on PET-CT. <i>Clinical Nuclear Medicine</i> , 2006, 31, 646-647.	0.7	19
65	FDG PET-CT Demonstration of Sjogren??s Sialoadenitis. <i>Clinical Nuclear Medicine</i> , 2005, 30, 698-699.	0.7	18
66	Targeted Î±-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 475-484.	0.7	17
67	Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. <i>Hellenic Journal of Nuclear Medicine</i> , 2009, 12, 26-9.	0.2	17
68	Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. <i>Theranostics</i> , 2020, 10, 3254-3262.	4.6	15
69	Role of Imaging in Prostate Cancer. <i>PET Clinics</i> , 2009, 4, 135-138.	1.5	14
70	Association of Overall Survival with Glycolytic Activity of Castrate-Resistant Prostate Cancer Metastases. <i>Radiology</i> , 2015, 274, 624-625.	3.6	14
71	Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque?. <i>Radiology</i> , 2017, 283, 1-3.	3.6	14
72	Management of Primary Osseous Spinal Tumors with PET. <i>PET Clinics</i> , 2019, 14, 91-101.	1.5	14

#	ARTICLE	IF	CITATIONS
73	Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. <i>Abdominal Radiology</i> , 2016, 41, 889-898.	1.0	13
74	Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1338-1339.	2.8	13
75	Role of ¹⁸ F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 216, 851-859.	1.0	13
76	FDG PET/CT Demonstration of Pancreatic Metastasis From Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2011, 36, 961-962.	0.7	12
77	[¹⁸ F]- ¹⁸ F-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (¹⁸ F-FMAU) in Prostate Cancer: Initial Preclinical Observations. <i>Molecular Imaging</i> , 2012, 11, 7290.2012.00004.	0.7	12
78	Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with ¹⁸ F-NaF PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 247-252.	0.6	12
79	Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and ¹⁸ F-FMAU PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, e426-e428.	0.7	11
80	PSMA PET: Transformational Change in Prostate Cancer Management?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 228-229.	2.8	11
81	The reproductive tract. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 262-273.	2.5	10
82	American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. <i>Journal of Nuclear Medicine</i> , 2015, 56, 642-645.	2.8	10
83	¹⁸ F-NaF/ ²²³ RaCl ₂ theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. <i>British Journal of Radiology</i> , 2018, 91, 20170948.	1.0	10
84	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020, 61, 552-562.	2.8	10
85	The SNMMI and EANM Practice Guideline for Tele-Nuclear Medicine 2.0. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 15-19.	0.4	9
86	Management Impact of ⁶⁸ Ga-DOTATATE PET/CT in Neuroendocrine Tumors. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 31-37.	0.6	9
87	Choline autoradiography of human prostate cancer xenograft: effect of castration. <i>Molecular Imaging</i> , 2008, 7, 147-52.	0.7	9
88	[¹⁸ F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (¹⁸ F-FMAU) in prostate cancer: initial preclinical observations. <i>Molecular Imaging</i> , 2012, 11, 426-32.	0.7	9
89	Can Choline PET Tackle the Challenge of Imaging Prostate Cancer?. <i>Theranostics</i> , 2012, 2, 331-332.	4.6	8
90	ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1174-1176.	2.8	8

#	ARTICLE	IF	CITATIONS
91	Targeted β -therapy in non-prostate malignancies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 47-53.	3.3	8
92	Prostate Cancer. <i>Methods in Molecular Biology</i> , 2011, 727, 265-290.	0.4	8
93	Molecular imaging of prostate cancer: a concise synopsis. <i>Molecular Imaging</i> , 2009, 8, 56-64.	0.7	8
94	Fusion Positron Emission Tomography β -Computed Tomography Demonstration of Epidural Metastases. <i>Clinical Nuclear Medicine</i> , 2004, 29, 39-40.	0.7	7
95	Gallium-68 β -Labeled Prostate-Specific Membrane Antigen β -11 PET/CT of Prostate and Nonprostate Cancers. <i>American Journal of Roentgenology</i> , 2019, 213, 286-299.	1.0	7
96	Colonic FDG Uptake Pattern in Subjects Receiving Oral Contrast With No Known or Suspected Colonic Disease. <i>Clinical Nuclear Medicine</i> , 2011, 36, 754-756.	0.7	6
97	Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2015, 3, 72-6.	0.1	6
98	Procedure guideline for telenuclear medicine 1.0. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1410-3.	2.8	6
99	Utility of a stimulus artifact suppressor for transesophageal pacing. <i>American Journal of Cardiology</i> , 1990, 65, 393-394.	0.7	5
100	ACR β -ASTRO Practice Guideline for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. <i>Clinical Nuclear Medicine</i> , 2011, 36, e72-e80.	0.7	5
101	Prognostic Utility of PET in Prostate Cancer. <i>PET Clinics</i> , 2015, 10, 255-263.	1.5	5
102	Radiotheranostics in Prostate Cancer: Introduction and Overview. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1S-2S.	2.8	5
103	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1836-1843.	2.8	5
104	Adenocarcinoma in an Indiana Pouch on PET-CT. <i>Clinical Nuclear Medicine</i> , 2007, 32, 57-58.	0.7	4
105	Preclinical evaluation of a ^{64}Cu -labeled disintegrin for PET imaging of prostate cancer. <i>Amino Acids</i> , 2019, 51, 1569-1575.	1.2	4
106	Value proposition of PSMA-targeted β -particle radioligand therapy in metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 8-10.	3.3	4
107	Prostate-specific antigen and prostate-specific antigen kinetics in predicting ^{18}F -sodium fluoride positron emission tomography-computed tomography positivity for first bone metastases in patients with biochemical recurrence after radical prostatectomy. <i>World Journal of Nuclear Medicine</i> , 2017, 16, 229-236.	0.3	4
108	Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants?. <i>Clinical Imaging</i> , 2016, 40, 1237-1245.	0.8	3

#	ARTICLE	IF	CITATIONS
109	SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 11-12.	2.8	3
110	Highlights of articles published in <i>annals of nuclear medicine</i> 2016. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1928-1933.	3.3	3
111	The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity. <i>Diagnostics</i> , 2017, 7, 43.	1.3	3
112	Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, e245-e246.	0.7	3
113	Point: The Existential Threat to Nuclear Medicine. <i>Journal of the American College of Radiology</i> , 2018, 15, 384-386.	0.9	3
114	A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy. <i>Canadian Urological Association Journal</i> , 2019, 14, 130-138.	0.3	3
115	Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences. <i>Clinical Nuclear Medicine</i> , 2020, 45, 668-671.	0.7	3
116	Competitive Advantage of PSMA Theranostics in Prostate Cancer. <i>Radiology</i> , 2021, 299, 261-263.	3.6	3
117	SNMMI Leadership Update: Developing Evidence-Based Appropriate Use Criteria under the Protecting Access to Medicare Act of 2014. <i>Journal of Nuclear Medicine</i> , 2015, 56, 20N.	2.8	3
118	"Alas, Poor Yorick!" <i>American Journal of Roentgenology</i> , 2002, 178, 178-178.	1.0	2
119	SNMMI Comment on ASCO 2013 "Choosing Wisely" Recommendation on Use of PET/CT in Recurrent Cancer Surveillance. <i>Journal of Nuclear Medicine</i> , 2014, 55, 699-700.	2.8	2
120	Multimodal imaging in focal therapy planning and assessment in primary prostate cancer. <i>Clinical and Translational Imaging</i> , 2017, 5, 199-208.	1.1	2
121	Management Impact of Metachronous Oligometastatic Disease Identified on 18F-Fluciclovine (Axumin, ¹⁸ F) PET/CT in Biochemically Recurrent Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2022, 24, 920-927.	1.3	2
122	Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer. <i>PET Clinics</i> , 2022, 17, 389-397.	1.5	2
123	Death Valley, California. <i>American Journal of Roentgenology</i> , 2002, 179, 1244-1244.	1.0	1
124	Advances in Imaging of Nonthyroid Endocrine Neoplasms. <i>Problems in General Surgery</i> , 2003, 20, 11-20.	0.2	1
125	Invited Commentary: Nuclear Theranostics "The Path Forward. <i>Radiographics</i> , 2020, 40, 1741-1742.	1.4	1
126	Effect of Androgen on Normal Biodistribution of [18F]-2 ¹⁸ F-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. <i>Anticancer Research</i> , 2017, 37, 475-480.	0.5	1

#	ARTICLE	IF	CITATIONS
127	SNMMI/ACR/ASNC/SCMR joint credentialing statement for cardiac PET/MRI. Journal of Cardiovascular Magnetic Resonance, 2022, 24, .	1.6	1
128	Gone Fishing. American Journal of Roentgenology, 2000, 175, 140-140.	1.0	0
129	Room with a View (North Coast of Aruba). American Journal of Roentgenology, 2001, 177, 806-806.	1.0	0
130	Raw and Ripe. American Journal of Roentgenology, 2001, 177, 886-886.	1.0	0
131	Joshua Tree National Park, California. American Journal of Roentgenology, 2002, 178, 110-110.	1.0	0
132	Yosemite, California. American Journal of Roentgenology, 2003, 181, 302-302.	1.0	0
133	Cancun, Mexico. American Journal of Roentgenology, 2003, 181, 1092-1092.	1.0	0
134	Preface. PET Clinics, 2009, 4, ix.	1.5	0
135	Influence of Trigger PSA and PSA Kinetics on ¹¹ C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. Journal of Nuclear Medicine, 2010, 51, 498.2-499.	2.8	0
136	Reply: Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know. Journal of Nuclear Medicine, 2018, 59, 715-716.	2.8	0
137	Single Institution Patterns of Management of (18)F-Fluciclovine-detected Prostate Cancer Recurrences. International Journal of Radiation Oncology Biology Physics, 2020, 108, E62-E63.	0.4	0
138	Imaging of Glycolysis with 18F-FDG PET. , 2017, , 87-94.		0
139	Editorial Comment. Journal of Urology, 2019, 202, 420-421.	0.2	0
140	Prostate Cancer Lymphangitic Pulmonary Carcinomatosis. Clinical Nuclear Medicine, 2020, 45, 727-729.	0.7	0
141	Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer. Radiology, 0, , .	3.6	0